Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A recent workshop at Pembroke College, Oxford, provided a showcase for research within the Arthritis Therapy Acceleration Programme (A-TAP) aimed at speeding up the delivery of new drugs for immune-mediated inflammatory disease (IMIDs).

A-TAP logo

The workshop was organised by the Kennedy Institute’s Director of Clinical Research and A-TAP lead, Prof Chris Buckley, to raise awareness of A-TAP and the funding opportunities it provides to support experimental medicine studies.

In opening remarks, Chris highlighted the importance of experimental medicine to overcome barriers in drug discovery. He explains, “Developments in our understanding of the genetic and cellular basis of disease have revealed that diseases traditionally classified as anatomically distinct share much more in common that previously recognized. Coupled with advances in biologic and cellular therapy and innovations in clinical trial design, it is now possible to run trials that have pathology-based outcome measures with one drug being studies across a ‘basket’ of different IMIDs”.

A-TAP was launched by the Universities of Oxford and Birmingham in 2017 to apply this new approach to trial design for development of novel treatments based on the underlying causes of inflammatory disease. The programme is supported by a £7M award from the Kennedy Trust for Rheumatology Research.

One way in which A-TAP facilitates clinical studies is to improve access to patients and diseased tissue samples. During the workshop, Dr Andrew Filer, an A-TAP investigator at the University of Birmingham, described his work on the Birmingham Early Arthritis Cohort (BEACON) to biopsy joint tissues when patients first show signs of inflammation in their joints. This approach is enabling research across the A-TAP network into early predictors and drivers of arthritis.

Robust and accurate tools to measure biological markers in tissues are also crucial to understand disease processes and how they are affected by drugs. Led by Dr Clare Verrill, University of Oxford, workshop participants also learned about the application of artificial intelligence approaches to measure pathology based markers across tissue samples from different types of inflammatory disease.

The workshop also gave a flavour of two new clinical studies enabled by A-TAP. These are exploring the effect of anti TNF therapy on tissue based markers in Rheumatoid Arthritis and Inflammatory bowel disease as well as the effect of three different biological therapies on cell populations in patients with ankylosing spondylitis

For more information about A-TAP and funding opportunities for Oxford and Birmingham based projects in the area of inflammatory arthritis, please contact A-TAP Operations Manager, Dr Claire Potter.

 

Similar stories

Immunology preprint reviews launched in Nature Reviews Immunology

Kennedy Main Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

A more tailored approach to treating psoriatic arthritis

Arthritis Botnar Funding Main

Dr Laura Coates has been awarded £1.8M from the National Institute for Health Research (NIHR) to explore the potential for precision medicine in the choice of biologics to reduce inflammation and pain in psoriatic arthritis.

Motion-capture to help children walk: Oxford team support new gait laboratory in Ethiopia

Main Orthopaedics and trauma

The Research at Oxford on Analysis of Motion (ROAM) team at the University of Oxford have supported CURE Ethiopia Children’s Hospital to develop and open a brand new gait laboratory, the first of its kind in the country and the only other active gait lab on the African continent outside of South Africa.

Professor Eleanor Stride recognised in New Year’s Honours list 2021

Awards Main

Statutory Professor of Biomaterials is awarded Officer of the Order of the British Empire (OBE) for services to Engineering

Drug may boost vaccine responses in older adults

Kennedy Main

A preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults

Living reviews launched by Oxford and Cardiff in the wake of COVID-19 research

Kennedy Main Research

In a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of “living reviews” in Oxford University Press’s new open access journal “Oxford Open Immunology”.